Navigation Links
Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
Date:10/17/2007

rug regimen in a single once-daily pill."

ATRIPLA was developed through a joint venture partnership between Bristol-Myers Squibb Company and Gilead Sciences. The product was approved by the U.S. Food and Drug Administration in July 2006 and has since become the most-prescribed treatment regimen for patients starting HIV therapy in the United States. In Canada, approximately 60,000 people are living with HIV, and around 2,500 new HIV diagnoses are reported each year.

Clinical data support the use of the three-drug regimen contained in ATRIPLA in HIV treatment-naive patients. A randomized, open label, active-controlled, multicenter, non-inferiority study, Study 934, compared a once-daily regimen of Viread, Emtriva and SUSTIVA, the components of ATRIPLA, with twice-daily Combivir(R) (lamivudine/zidovudine) and once-daily SUSTIVA in treatment-naive patients with HIV. Through 48 weeks, 84 percent of patients in the Viread/Emtriva/SUSTIVA group (n=244) compared to 73 percent of patients in the Combivir/SUSTIVA group (n=243) achieved and maintained a viral load of less than 400 copies/mL. This difference largely results from the higher number of discontinuations in the Combivir/SUSTIVA group due to adverse events (9 percent vs. 4 percent in the Viread/Emtriva/SUSTIVA group) and other reasons including loss to follow-up, patient withdrawal, non-compliance and protocol violation (14 percent vs. 10 percent in the Viread/Emtriva/SUSTIVA group).

In addition, 80 percent and 70 percent of patients in the Viread/Emtriva/SUSTIVA group and the Combivir/SUSTIVA group, respectively, achieved and maintained a viral load less than 50 copies/mL through 48 weeks. Selected treatment-emergent adverse events (Grades 2-4) reported in greater than or equal to 5 percent of patients in the Viread/Emtriva/SUSTIVA group through 48 weeks included dizziness, nausea, diarrhea, fatigue, headache and rash.

Important Product Safety Information About ATRIPLA (efavirenz 600 mg/emtr
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
2. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
3. Nationwide MRSA Prevalence Study to Demonstrate Full Scope of Superbug Threat Facing U.S. Healthcare Facilities and Patients
4. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
5. Data Showing that ReGens Colostrinin Supports Healthy Cognitive Function Presented at the 2007 International Congress on Natural Medicine in Australia
6. Antidepressant Use May Boost Fracture Risk, From Harvard Womens Health Watch
7. FDLI 50th Annual Meeting Heralds New ERA in Healthcare Innovations, FDA Regulations
8. New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory Properties and Increased Health Benefits
9. Actilyse (alteplase) Recommended by National Institute for Health and Clinical Excellence for Treatment of Acute Ischaemic Stroke
10. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
11. Eighty-one Percent of U.S. Adults say that Birth Control Pills and Procedures Should Be Covered by Health Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 /CNW/ - Bedrocan Cannabis Corp., previously Bedrocan ... to its Board of Directors, enhancing executive oversight ... company, a leading licensed producer of medicinal cannabis ... has 13 years, experience in producing and supplying ... including Canada. As previously announced ...
(Date:8/21/2014)... 21, 2014  SI-BONE, Inc. ( San Jose, ... the use of the iFuse Implant System, ® ... of the sacroiliac (SI) joint, announced that Priority Health ... its Lumbar Fusion Medical Policy No. 91590-R4 providing positive ... policy states that the fusion procedure, which employs the ...
(Date:8/20/2014)... , Aug. 20, 2014 Northstar ... announced that after months of hard work from ... the new Snorenz formulation and package design.  The ... and B-6 back into the product due to ... longer lasting effects.  Snorenz Nighttime will also include ...
Breaking Medicine Technology:Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3Northstar completes the first phase of its new retail strategy and prepares to ship reformulated Snorenz with all new packaging 2
(Date:8/21/2014)... (HealthDay News) -- Researchers report that children with autism ... in their brains compared with typical children. The ... the number of extra synapses through drug treatment. ... cells (neurons) connect and communicate with each other. Having ... the brain functions, theorized neuroscientists at Columbia University Medical ...
(Date:8/21/2014)... Angeles, CA (PRWEB) August 21, 2014 ... talk show “Heavy Metal Greg” will screen on Monday, ... Action on Film International Film Festival. This festival is ... several companies, including Video Symphony, Sony Software, Avid, and ... California, at Cinema 12 & LFX, located at 410 ...
(Date:8/21/2014)... and health authorities need to ensure that experimental drugs ... context of randomized controlled trials, according to a new ... 21 August, 2014]. , Leading bioethicists Professor ... and Dr Annette Rid, of King,s College London, UK, ... to if experimental drugs are to be deployed in ...
(Date:8/21/2014)... One of the emerging trends that the Intranasal ... increasing adoption of non-invasive administration products. As non-invasive nasal ... their convenient application, they find more preference among end-users. ... used for the administration of drugs for the treatment ... such as allergic and non-allergic rhinitis and sinusitis. The ...
(Date:8/21/2014)... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast, 2012 - 2018," the ... million in 2011 and is estimated to reach a ... CAGR of 6.3% from 2012 to 2018. , Browse ... , Fundus cameras market growth in recent years has ...
Breaking Medicine News(10 mins):Health News:Kids With Autism Have Extra Brain Connections, Study Says 2Health News:“Heavy Metal Greg,” a Music Talk Show by Gregory Graham, Will Screen at Action on Film International Film Festival on 08/25/2014 2Health News:The Lancet: Experimental Ebola drugs must be fairly distributed and tested ethically in clinical trials 2Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 2Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 3Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 4Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 5Health News:Fundus Cameras Market: Product Type- Mydriatic, Non-Mydriatic, Hybrid and ROP Cameras; End Users- Hospitals, Ophthalmology Clinics and Ophthalmic & Optometrist Offices 2
... Fitness Event at the Quicken Loans Arena on June 18th -- Join ... ... LeBron James and Mayor Frank Jackson,invite Cleveland residents to join a ... well-being with a FREE,health and fitness plan -- the Cleveland City Challenge. ...
... Manpower Support Cutting-Edge ... Manufacturing Activities, SAN ... a leading manufacturing hub in Asia with its strong,track record, ... output expanded,four-fold from US$4.4 billion in 2000 to US$17 billion ...
... Inc. Director of Internal Controls Adds to SAND,s ... ... SAND Technology Inc. (OTC,Bulletin Board: SNDTF), an international provider ... Schwartz,has joined the firm as Chief Financial Officer and Vice ...
... off diabetes meds and into remission, study found , , ... a major role in improving diabetes after obese patients ... , Previous studies have suggested that gastric bypass ... the stomach to the small intestine -- helps improve ...
... University of Florida department of urology officials ... German biopharmaceutical company CureVac to test an experimental ... longer respond to traditional treatment. , CureVac ... RNA, a biomolecule that transfers genetic information from ...
... over the last fifteen years in national accreditation guidelines ... a right, there is no evidence yet that this ... hospitals with chaplains. Rather, new research from Brandeis University ... Journal reports that whether hospitals had a chaplain ...
Cached Medicine News:Health News:NBA All-Star and Olympic Athlete LeBron James and Dr. Ian Smith Celebrate the Launch of The 50 Million Pound Challenge's First 'Citywide Team Challenge,' Kicking off in Cleveland, Ohio 2Health News:NBA All-Star and Olympic Athlete LeBron James and Dr. Ian Smith Celebrate the Launch of The 50 Million Pound Challenge's First 'Citywide Team Challenge,' Kicking off in Cleveland, Ohio 3Health News:Singapore Reinforces Position as a Global Site for Pharma & Biotech; Biomedical Manufacturing Output Quadruples to Reach US$17 Billion 2Health News:Singapore Reinforces Position as a Global Site for Pharma & Biotech; Biomedical Manufacturing Output Quadruples to Reach US$17 Billion 3Health News:Singapore Reinforces Position as a Global Site for Pharma & Biotech; Biomedical Manufacturing Output Quadruples to Reach US$17 Billion 4Health News:SAND Technology Appoints Zainab Ahmed Schwartz as CFO 2Health News:Weight Loss After Gastric Bypass Is Key to Easing Diabetes 2Health News:UF scientists to work with German firm in prostate cancer treatment research 2Health News:When the spirit moves into the hospital 2
... Practice management software for ... a true multi-tasking, multi-office practice ... in database technology- Winx Pro ... will assist you in effectively ...
The XT-1800i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
The SE-9000 automated hematology analyzer provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test results for enhanced screening ability....
... offers three-dimensional VCS technology, ... and efficiency in white ... analysis. With its reputation ... HmX is an affordable ...
Medicine Products: